Multiple types of gene changes may cause glial cells to grow into tumors. IDH-mutant gliomas have changes in the IDH1 or IDH2 gene. These genes instruct your body to produce isocitrate ...

Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed.

The research team, led by Dr. Avishay Spitzer, found that the drug, which works by inhibiting the mutant IDH enzyme, caused the cells to alter the gene program that they expressed. In fact ...

The Phase 3 INDIGO Trial was presented in the 2023 ASCO Presidential Plenary session. Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A ...

For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study ...

A new research paper was published in Oncotarget, Volume 16, on March 27, 2025, titled "Imipridones ONC201/ONC206 + RT/TMZ ...

tells SurvivorNet it’s a “game-changer” for patients with IDH-mutated, grade two glioma. Glioma is a primary brain tumor that originates from the glial cells present in the central nervous ...

1 Recommendations 1.2 and 1.5 of that guideline stated that initial therapy with radiation and chemotherapy may be deferred in select patients with IDH-mutant WHO CNS grade 2 oligodendroglioma and ...